Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Target |
Action inhibitors |
Mechanism ITK inhibitors(Tyrosine-protein kinase ITK/TSK inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC43H51N9O6 |
InChIKeyZLOIRWPQMNYBGL-SFCXHYMASA-N |
CAS Registry3034476-33-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | China | 23 Mar 2023 | |
T-Cell Lymphoma | Preclinical | China | 23 Mar 2023 |